Alonso FB, Ramos VJR, Agüero AMC

Language: Spanish
References: 18
Page: 38-45
PDF size: 207.43 Kb.

ABSTRACT

It carried out a study of a cross-sectional descriptive of patients diagnosed with gastrointestinal stromal tumor. The study population consisted of six patients who underwent excisional biopsy in 2011 at “Arnaldo Milian Castro” Clinical Surgical Hospital of the City of Santa Clara, Villa Clara province. The samples were processed in the Department of Pathology of the same institution, through morphological and immunohistochemical methods, the diagnosis of gastrointestinal stromal tumors were offered. Tumor size, location and the mitotic index, which showed that 57.1% behaved as high risk: To characterize the morphological and immunohistochemical prognostic factors in these tumors and predict their biological behavior of the macro and microscopic morphological parameters were determined. Mienttinen prognostic and Lasota classification was used and immunohistochemistry showed positive to CD117 in 100% of cases, the Ki67 proliferative activity was low at 42.1% of the tumors. The evaluation of the biological behavior of the tumor in patients diagnosed with gastrointestinal stromal tumor in the hospital, according to the index Mienttinen and Lasota, was considered high risk in 57% of patients studied.

REFERENCES

1. Vinay K, Pritzker N, Abbas AK. Robbins Basic Pathology. 9na ed. Chicago: Elsevier; 2013.

2. Martín Gil J, García Marín A, Vaquero Rodríguez A, Sánchez Rodríguez T, Camarero Mulas C, Pérez Díaz MD, et al. Gist gástrico gigante. Rev Esp Enferm Dig. 2009;101(12):881-9.

3. Streutker CJ, Huizinga JD, Driman DK, Ridell RH. Interticial cells of Cajal in heallth and disease. Histopathology. 2007 Jan;50(2):176-89.

4. The WHO Classification of Tumours of the Digestive System, World Health. Lyon: IARC Press; 2006.

5. Mientinen M, Lasota J. Prognosis of primary GIST. Semin Diagn Pathol. 2006 May;23(2):70-83.

6. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

7. Heinrich BP, Rubin BJ. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-95.

8. Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 Jan 23;279(5350):577-80.

9. Miettinen M, Lasota J. Prognosis of primary GIST. Semin Diag Pathol. 2006; May;23(2):70-83

10. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recentadvances in understanding of their biology. Huma Pathol. 1999;30:1213-20.

11. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumors of tehgastrointestinal tract and in mesenterio fibromatosis. Histopathology. 1994;25:469-73.

12. Suster S. Gastrointestinal stromal tumors. Sem Diagnost Pathol. 1996 Nov;13(4):297-313.

13. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;Jan;29(1):52-68.

14. Emory TS, Sobin LH, Lukes L y col. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Am J Surg Pathol. 1999;23:82-7.

15. Tumor del estroma gastrointestinal. (GIST). Clinica las condes. Rev Med Clin 2008;19(4):381-84.

16. Nafussi AA, Wong NACS. Intrabdominal spindle cell lesions: a review and practical aids todiagnosis. Histopathol. 2001;38:387-402.

17. Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–56.

18. Miettinen M, Zeng-Feng Wang, Lasota J. DOG1 Antibody in the Differential Diagnosis of Gastrointestinal stromal tumors, A study of 1840 cases. Am J Surg Pathol. 2009 Sep;33(9):1401-8. doi: 10.1097/PAS.0b013e3181a90e1a.